Drugs · acquisition-cost intelligence
LAMICTAL XR
Lamotirigine· ingredient lamotrigineOther antiepileptics· LAMOTRIGINE 100 mg/1; LAMOTRIGINE 200 mg/1; LAMOTRIGINE 250 mg/1; LAMOTRIGINE 25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.77451
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other lamotrigine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| LAMOTRIGINE Kit | $0.04556 | −$0.72890 |
| Lamotrigine | $0.07759 | −$0.69690 |
| lamotrigine | $0.16332 | −$0.61120 |
| LAMICTAL | $1.60 | +$0.82210 |
Medicare Part D coverage · CY2026
On 190 plan formularies · typical tier 4
Prior auth 0% · Step therapy 28% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.